New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 14, 2012
05:01 EDTBRCM, BA, CLNE, DKS, SODA, EXEL, CSCO, WPRT, GILD, HD, SAND, O, QCOM, GE, CELG, DVAXJim Cramer's "Mad Money"
Jim Cramer said there are plenty of reasons to still own stocks. As many are still hopeful for a deal that can avert the fiscal cliff. So why haven't stock prices cratered in the meantime? Cramer said there are many reasons. Many investors simply aren't aware of drastic consequences if a deal is not reached, while others have their investments in IRAs and other tax-favored accounts that may not be affected by the fiscal cliff. Those investors are buyers into weakness and help provide a cushion for the markets, Cramer said. Then there are the earnings, strong earnings, from the likes of Home Depot (HD) and Dicks Sporting Goods (DKS), which prove that Americans are still spending, especially on their homes. Other big moves, including from biotechs like Celgene (CELG) and Gilead Sciences (GILD), are hard to pass up, Cramer continued. In the end, being out of the market when a deal is reached would be a huge mistake, Cramer said, as even a bad outcome is better than no outcome at all. EXECUTIVE DECISION: Cramer once again sat down with Andrew Littlefair, CEO of Clean Energy Fuels (CLNE), a stock that's been cut in half since its highs earlier this year, but also one that received a boost Tuesday on the news that the company is building two liquefied natural gas plants with General Electric (GE). Littlefair said ultimately, Clean Energy plans 10 such plants, allowing the company to provide fuel along the major interstate corridors across our country. When Westport Innovations (WPRT) introduces the next-generation natural gas engines in February, Littlefair added, that will likely be the catalyst to convince many more truckers to begin using natural gas and start saving up to $1.50 per gallon in fuel costs. Cramer said Littlefair made him feel more upbeat on the prospects for natural gas in America. OFF THE CHARTS: Cramer and colleague Bob Lang went over the chart of Boeing (BA), one that is squarely in the crosshairs of the looming fiscal cliff. With a floor at $69 a share, Lang said investors have decent downside protection at these levels. More importantly, Boeing's recent rally now puts the stock above its 10-day, 50-day and 200-day moving averages, which makes it an "up stock" in the eyes of technicians who follow it. Cramer said there's a tremendous buying cycle at hand in the aerospace world, as more and more airlines need to add more fuel efficient planes to their fleets. This cycle lasts for years, he said, which is why Boeing is one stock that can fly higher than even the fiscal cliff. NO HUDDLE OFFENSE: Cramer took a moment out to praise the management at Home Depot and Dicks Sporting Goods for their remarkable earnings.Home Depot. LIGHTNING ROUND: (Bullish) QCOM; CSCO; BRCM; O; EXEL; DVAX. (Bearish) SAND; SODA.is now set to ride the waves of a recovering housing market and the rebuilding effort after Hurricane Sandy. Cramer said Dick's 5% pop in same store sales was remarkable during a time when many are not necessarily in the market for expensive sneakers or outdoor sporting gear. Reference Link
News For HD;DKS;CELG;GILD;CLNE;GE;WPRT;BA;QCOM;CSCO;BRCM;O;EXEL;DVAX;SAND;SODA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
January 13, 2015
07:24 EDTCELGCelgene 2015 guidance conservative, says Cantor
Subscribe for More Information
06:50 EDTBABoeing, Airbus could be hurt by oil tumble, NY Times says
Subscribe for More Information
05:32 EDTDKSDick's Sporting initiated with an In-Line at Imperial Capital
Target $60.
05:29 EDTBABoeing records $232.7B in commercial net in orders in 2014
Subscribe for More Information
January 12, 2015
18:24 EDTBASymantec acquires staff, licenses from Boeing's Narus, WSJ reports
Subscribe for More Information
16:12 EDTCELGAgios announces Celgene agrees to exercise option to license AG-120
Agios Pharmaceuticals (AGIO) announced that its collaboration partner Celgene (CELG) has agreed that it will exercise its option to obtain an exclusive license outside the United States for AG-120, a first-in-class, oral, potent inhibitor of the mutant IDH1 protein under the terms of the 2010 collaboration agreement. This would be the second IDH mutant inhibitor to be licensed by Celgene in less than a year. AG-120 is currently being evaluated in two Phase 1 dose escalation trials, one in advanced hematologic malignancies and the other in advanced solid tumors. Both trials are evaluating AG-120 in patients whose cancer harbors an IDH1 mutation. The first data from the AG-120 program were presented at the EORTC-NCI-AACR Symposium on November 19, 2014 in advanced hematologic malignancies. Agios expects to report the first data from the Phase 1 advanced solid tumor trial at a medical conference in 2015. Celgene's exercise of the option is subject to receipt of any required regulatory approvals including any applicable clearance under the Hart-Scott-Rodino Act.
12:10 EDTCELGRBC Capital says Celgene's shares could rise to $200 'over time'
The long-term profit guidance that Celgene (CELG) released today suggests that the stock, currently trading around $115, could reach $200 "over time," RBC Capital wrote in a note to investors today. WHAT'S NEW: After Celgene estimated that its EPS would exceed $12.50, excluding certain items, by 2020, RBC Capital says that the guidance exceeded the firm's previous outlook. RBC added that Celgene's projection increases its confidence in the predictability of the drug maker's performance over the longer term. The firm recommended that investors own Celgene in 2015, noting that the company has the potential to settle its patent case with Actavis (ACT). A settlement would enable investors to focus on Celgene's visible long-term growth and the robust opportunity provided by its drugs in development, RBC stated. Historically, investors have not given Celgene credit for these strengths, the firm stated. PRICE ACTION: In early afternoon trading, Celgene rose 1.5% to $115.35.
11:09 EDTCELGCelgene sees 2020 adjusted EPS over $12.50, sales above $20B
Subscribe for More Information
11:06 EDTCELGCelgene backs FY17 target for adjusted EPS $7.50, sales $13B-$14B
Subscribe for More Information
11:03 EDTCELGCelgene sees FY15 Revlimid sales $5.6B-$5.7B
Subscribe for More Information
11:02 EDTCELGCelgene sees Q4 adjusted EPS $1.01, consensus 99c
Subscribe for More Information
11:02 EDTCELGCelgene sees FY14 adjusted EPS $3.71, consensus $3.69
Sees FY14 net product sales $7.56B, consensus $7.66B. Sees FY14 Revlimid sales $4.98B, Abraxane sales $848M, Pomalyst/Imnovid sales $680M and Otezla sales $70M.
10:59 EDTCELGCelgene sees FY15 adjusted EPS $4.60-$4.75, consensus $4.84
Subscribe for More Information
10:56 EDTCELGCelgene says no higher priority that accelerating development of Crohn's drug
Subscribe for More Information
10:53 EDTCELGCelgene says Otezla scripts accelerated in Q4
10:51 EDTCELGCelgene reports FY14 EPS $3.71, consensus $3.69
Subscribe for More Information
10:44 EDTCELGCelgene CEO says company expects to meet, exceed 2017 guidance
The company is speaking at JPMorgan's conference.
09:34 EDTGILDActive equity options trading
Subscribe for More Information
06:39 EDTBAAir Lease delivers eight Boeing 777-300ER aircraft this year
Air Lease (AL) announced that, pursuant to long term lease agreements, ALC will deliver eight new Boeing 777-300ER widebody aircraft to six different airlines in 2015, all from ALC's order book with Boeing (BA). The following airlines are scheduled to take delivery of these new ALC Boeing 777-300ERs in 2015: Air France, Emirates, Korean Air, EVA Air, KLM, and Ethiopian Airlines.
06:28 EDTCSCOCisco positioned for better than expected quarter, says Deutsche Bank
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use